New Triple-Drug attack shows promise against tough leukemia
NCT ID NCT07407140
First seen Feb 15, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests whether a three-drug combination (VAG) works better than standard chemotherapy for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 people aged 14 to 74 will be randomly assigned to receive either the new triple-drug regimen or standard chemo plus a targeted drug. The goal is to see which approach improves survival and reduces cancer cells more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.